PLoS ONE (Jan 2019)

Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS.

  • Amaya Rando,
  • Miriam de la Torre,
  • Anna Martinez-Muriana,
  • Pilar Zaragoza,
  • Antonio Musaro,
  • Sara Hernández,
  • Xavier Navarro,
  • Janne M Toivonen,
  • Rosario Osta

DOI
https://doi.org/10.1371/journal.pone.0210752
Journal volume & issue
Vol. 14, no. 1
p. e0210752

Abstract

Read online

Amyotrophic lateral sclerosis (ALS) is a lethal motor neuron disease with no cure. Currently there are only two ALS drugs approved by the FDA, both with a limited therapeutic effect. In the search for drug candidates for ALS, we studied the effect of known stem cell mobilizing agents (treatment) and antimetabolite 5-fluorouracil (5-FU) (anti-treatment) in SOD1G93A model of ALS. Surprisingly, we found that anti-cancer drug 5-FU increases lifespan, delays the disease onset and improves motor performance in ALS mice. Although we were not able to demonstrate the mechanistic basis of the beneficial 5-FU action in ALS mice, our findings suggest that 5-FU or similar drugs are possible drug candidates for the treatment of motor neuron diseases through drug repurposing.